Big projects are priority as threat from generic Advair looms.
Sucampo gains rights to a drug for rare genetic disorder.
Japanese pharma swoops after strong phase 2a results.
Deal set to close in Q2.
Phase 3 data confirmed its efficacy in patients with a certain mutation.
PTC says it will make changes to the price after abandoned launch last month.
Activist investor’s intervention adds to buzz surrounding BMS.